Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Nov 15:4:69.
doi: 10.1186/s40425-016-0175-4. eCollection 2016.

TCR diversity - a universal cancer immunotherapy biomarker?

Douglas G McNeel  1
Affiliations
Editorial

TCR diversity - a universal cancer immunotherapy biomarker?

Douglas G McNeel. J Immunother Cancer. .

Abstract

Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.

Keywords: Prostate cancer; Sipuleucel-T; T-cell diversity; TCR sequencing; Tumor vaccine.

PubMed Disclaimer

Comment on

References

    1. Couzin-Frankel J. “Breakthrough of the year 2013.” Cancer immunotherapy. Science. 2013;342:1432–3. doi: 10.1126/science.342.6165.1432. - DOI - PubMed
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. “Sipuleucel-T immunotherapy for castration-resistant prostate cancer.”. N Engl J Med. 2010;363:411–22. doi: 10.1056/NEJMoa1001294. - DOI - PubMed
    1. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. “Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.”. J Urol. 2011;186:877–81. doi: 10.1016/j.juro.2011.04.070. - DOI - PubMed
    1. Madan RA, Gulley JL, Fojo T, Dahut WL. “Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.”. Oncologist. 2010;15:969–75. doi: 10.1634/theoncologist.2010-0129. - DOI - PMC - PubMed
    1. Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. “PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.”. Cancer Immunol Res. 2015;3:946–55. doi: 10.1158/2326-6066.CIR-14-0206. - DOI - PMC - PubMed